Introduction
Heparin induced-thrombocytopenia (HIT) is a life-threatening rare complication of heparin therapy. Its pathogenesis includes the formation of antibodies against platelets, which eventually lead to paradoxical thrombotic complications. [1] [2] [3] Venous thrombosis is far more common than arterial thrombosis in HIT, although both occur.
In patients with HIT, native coronary arteries are rarely implicated by thrombus formation and this almost always occurs in the setting of venous coronary grafts or previous coronary interventions. [4] [5] [6] [7] [8] [9] [10] Here,
Learning points
• Heparin-induced thrombocytopenia (HIT) can lead to acute coronary thrombosis leading to ST-elevation myocardial infarct.
• ST-elevation myocardial infarct can be the only manifestation of HIT in critically ill patients, and high index of suspicion is required when thrombocytopenia is noted. we describe a case of thrombus formation in a native coronary artery causing an ST-elevation myocardial infarct (STEMI) secondary to HIT.
Timeline Case summary
The patient is a 67-year-old woman with a history of hypertension, acute kidney failure, a provoked pulmonary embolism needing an inferior vena cava (IVC) filter placement due to gastro-intestinal bleed, who presented with bilateral lower extremity swelling and pain. She is not known to have ischaemic heart disease or previous angina symptoms.
Her symptoms have been progressively worse over the past few weeks. On initial presentation to the hospital, she was haemodynamically stable with a temperature of 36. 3 C, heart rate of 117 b.p.m., respiratory rate of 20/min, blood pressure of 113/55 mmHg, oxygen saturation of 100% on room air. She was alert and oriented, not in acute distress. Her lungs were clear on auscultation and her heart sounds were normal and regular. Her lower extremities were erythematous, warm, painful to touch, and presented a non-pitting oedema bilaterally. Laboratory studies were significant for a creatinine of 3.8 mg/dL from a baseline of 0.8 mg/dL (normal 0. 7.5 . A nuclear lung perfusion scan was performed and showed evidence of subsegmental areas of decreased activity in both lungs, the right more than the left, suggestive of pulmonary emboli. Angiography revealed that the thrombosis is extending to IVC filter and bilateral renal veins. In this perspective, she received local thrombolysis through two ultrasound-assisted catheters-directed thrombolysis (tissue plasminogen activator at a rate of 0.5 mg/h for a total of 10 mg in combination with heparin) and was also started on systemic intravenous heparin treatment. Thereafter, she was transitioned to apixaban for anticoagulation and the heparin was stopped. Due to the extent of the thrombosis, the patient underwent a repeat local cathetersdirected thrombolysis. Subsequently, her course was complicated by right lower extremity compartment syndrome, for which she underwent a partial fasciotomy and was switched to intravenous heparin treatment in the peri-operative phase. She developed a sudden onset of substernal chest pain and an electrocardiogram showed STelevation in leads II, III, and AVF. Subsequently, she underwent coronary angiography, which confirmed a thrombus formation in the distal portion of the right coronary artery (RCA) ( Figure 1A ; also Supplementary material video (pre stenting)). The rest of the coronary angiography showed that the left main artery had a 20% stenosis, the left anterior descending artery had 50% stenosis, and the left circumflex artery had diffuse irregularities. Thrombus aspiration was not performed, but the lesion was crossed using a Prowater wire followed by a 2.5 mm Trek balloon inflation. A drug-eluting stent was placed successfully with return of TIMI III flow in the RCA ( Figure 1B) ; also Supplementary material video (post stenting)). A recent transthoracic echocardiogram was reviewed and showed an intact atrial septum without evidence of an atrial septal defect or patent foramen ovale confirmed by agitated saline study. A follow-up echocardiogram post-myocardial infarction showed hypokinesis of the mid infero-lateral segment, akinesis of the basal inferior segment. All other segments appeared to contract normally. She also was noted to have a new onset thrombocytopenia, with a platelet nadir of 109 000/mL from baseline of 271 000/mL (>50% drop from baseline) within 6 days of heparin reintroduction. Her other laboratory tests included haemoglobin of 8.3 g/dL and creatinine of 1.4 mg/dL. Calculation of the 4T score revealed a count of 7, which implied a 64% probability of having HIT. Heparin-PF4 IgG antibody (1.297 optical density, normal <0.4000) and serotonin release assay were positive, confirming the diagnosis of HIT. The decision was to treat her with apixaban 5 mg twice daily. She was discharged on triple therapy with aspirin 81 mg daily, ticagrelor 90 mg twice daily with a plan to continue on dual-antiplatelet therapy for 1 year, and apixaban for lifelong anticoagulation. The patient's platelets and kidney function were back to normal within days ( Figure 2 
Discussion
Heparin-induced thrombocytopenia is a well-recognized immunological phenomenon secondary to heparin exposure. It is estimated that the risk of developing HIT after exposure to unfractionated heparin to be 2.6%. 1, 2 The underlying pathogenesis involves the development of antibodies against platelet factor 4 (PF4) bound to heparin, called HIT antibodies. Those immunoglobulins can bind to platelets and cause a wide-spread platelet activation leading to venous and arterial thrombosis and activation of coagulation cascades. This eventually leads to platelet consumption and thrombocytopenia. Clinically, these events tend to occur within 5-14 days of initiation of heparin, especially in the setting of previous heparin exposure. High index of suspicion with the aid of scoring systems such as '4T' score is required for the diagnosis of HIT. The pattern of thrombosis in HIT tends to be dominant on the venous side. However, arterial thromboembolic complications can occur causing, commonly, limb ischaemia. 3 Coronary thrombosis can rarely occur in association with HIT. This can manifest in acute myocardial ischaemia and can be a lifethreatening emergency when it occurs. There had been previous reported cases of HIT causing coronary thrombus formation, however most in the setting of either previous coronary intervention, stenting or in coronary bypass grafts. [4] [5] [6] [7] [8] [9] [10] Upon review of the literature, we identified multiple case reports of HIT complicated by coronary arterial thrombosis ( Table 1) . Female-to-male ratio was 2:1. All of the cases were preceded by initiation of unfractionated heparin. The time until thrombocytopenia ranged from 1 h to 96 h, with an average of 35 h, since the initiation of heparin. The platelet nadir ranged from 4 Â 10 9 to 109 Â 10 9 per mL, with an average of 5 Â 10 9 per mL. Time until coronary artery thrombosis ranged from 0 h to 96 h, with an average of 24 h, since the initiation of heparin. There was only one case of HIT that involved a native, not previously treated, coronary artery. 9 Our case heightens the awareness of the possibility of thrombotic complications of HIT in native coronary arteries. This is important, as early recognition and treatment of coronary thrombosis with HIT requires immediate discontinuation of all heparin products and 
initiation of anticoagulation with different agents in efforts to prevent further progression. 3 The general management of the myocardial infarction itself would remain the same. This would include dual antiplatelet therapy, beta-blockers, statins and angiotensin I converting enzyme inhibitors if required. Urgent PCI is necessary for STEMI and in certain cases of Non-STEMI. 11 An alternative form of anticoagulation in patients with HIT stops the progression of the disease and further antibody formation, and resolves further thrombosis due to platelet activation. Alternatives usually include direct thrombin inhibitors such as argotraban or bivalirudin, fondaparinux, danaparoid, or direct oral anticoagulants (DOACs) such as apixaban or rivaroxaban. The choice of anticoagulant is dependent upon factors that include the patient's renal and hepatic function, as well as the acuity of the patient's thrombotic complications. 3 There are previous reports of using DOACs successfully in the initial management of HIT. 12 However, this experience in using DOACs in HIT is limited and is mostly using rivaroxaban. It was shown that apixaban may provide an option for an oral alternative for patients with HIT as it did not cause platelet activation. 13 Our patient received apixaban as sole alternative anticoagulation with resolution of thrombocytopenia and no progression or recurrence of thrombosis.
Conclusion
Heparin-induced thrombocytopenia-associated coronary artery thrombosis is a rare, but life-threatening, complication. Here, we present a case of a native coronary thrombus that developed in a patient with HIT causing a STEMI. This provides further proof that clinicians should be aware of this deadly complication, as early treatment is life saving. We also show that this can occur even in a previously untreated native coronary artery. Further, our case supports the successful use of apixaban as monotherapy in the treatment of HIT along with the usual management of acute coronary syndromes.
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